Key facts
- It has raised $330K across 1 recorded rounds; the latest was Seed Round ($647K) in Jul 2025.
- Notable investors include Chen Lab, Incate.
- Paralos Bioscience has filed 4 Form Ds with the SEC since 2025, most recently Jun 2026 ($647K sold to 5 investors).
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Paralos Bioscience
Create free account
No card required
Funding rounds
1 roundsAbout Paralos Bioscience
Developer of a phage-drug conjugate delivery platform designed to improve therapeutic development approaches for major global health challenges. The company is currently operating in Stealth mode.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2024
- Employees
- 5
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Paralos Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Paralos Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Paralos Bioscience in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.